TriangleNCT00952289 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- From randomization to the data cut-off date (up to 14 months).
What was measured
Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.
Analysis population: ITT population
Groups in this outcome
Ruxolitinib
Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.
Placebo
Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting pre-specified requirements were given the opportunity to cross over to ruxolitinib treatment.
| Group | Source count |
|---|---|
| Ruxolitinib | 155 |
| Placebo | 154 |
Reported measurements
Death events
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ruxolitinib | 10 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 14 | Not reported | Not reported | Not reported | Not reported |
Censored events
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ruxolitinib | 145 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 140 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 10
- group Id
- OG001
- value
- 14
- title
- Death events
- categories
- measurements
- group Id
- OG000
- value
- 145
- group Id
- OG001
- value
- 140
- title
- Censored events
- denoms
- counts
- group Id
- OG000
- value
- 155
- group Id
- OG001
- value
- 154
- units
- Participants
- description
- Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.
- groups
- description
- Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.
- id
- OG000
- title
- Ruxolitinib
- description
- Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting pre-specified requirements were given the opportunity to cross over to ruxolitinib treatment.
- id
- OG001
- title
- Placebo
- param Type
- NUMBER
- population Description
- ITT population
- reporting Status
- POSTED
- time Frame
- From randomization to the data cut-off date (up to 14 months).
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice